Early detection and surveillance of SARS-CoV-2 genomic variants in wastewater using COJAC

Katharina Jahn1,2,8, David Dreifuss1,2,8, Ivan Topolsky1,2,8, Anina Kull3, Pravin Ganesanadamooorthy3, Xavier Fernandez-Cassi4, Carola Bänziger3, Alexander J. Devaux3, Elyse Stachler3, Lea Caduff3, Federica Cariti3, Alex Tuñes Corzón3, Lara Fuhrmann1,2, Chaoran Chen1,2, Kim Philipp Jablonski1,2, Sarah Nadeau1,2, Mirjam Feldkamp1, Christian Beisel1, Catharine Aquino5, Tanja Stadler1,2, Christoph Ort1,3, Tamar Kohn4, Timothy R. Julian3,6,7 and Niko Beerenwinkel1,2

The continuing emergence of SARS-CoV-2 variants of concern and variants of interest emphasizes the need for early detection and epidemiological surveillance of novel variants. We used genomic sequencing of 122 wastewater samples from three locations in Switzerland to monitor the local spread of B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) variants of SARS-CoV-2 at a population level. We devised a bioinformatics method named COJAC (Co-Occurrence adJusted Analysis and Calling) that uses read pairs carrying multiple variant-specific signature mutations as a robust indicator of low-frequency variants. Application of COJAC revealed that a local outbreak of the Alpha variant in two Swiss cities was observable in wastewater up to 13 d before being first reported in clinical samples. We further confirmed the ability of COJAC to detect emerging variants early for the Delta variant by analysing an additional 1,339 wastewater samples. While sequencing data of single wastewater samples provide limited precision for the quantification of relative prevalence of a variant, we show that replicate and close-meshed longitudinal sequencing allow for robust estimation not only of the local prevalence but also of the transmission fitness advantage of any variant. We conclude that genomic sequencing and our computational analysis can provide population-level estimates of prevalence and fitness of emerging variants from wastewater samples earlier and on the basis of substantially fewer samples than from clinical samples. Our framework is being routinely used in large national projects in Switzerland and the UK.

The ongoing spread and evolution of SARS-CoV-2 has generated several variants of interest and variants of concern (VOC)1–3, which can affect, to different degrees, transmissibility4, disease severity4, diagnostics and the effectiveness of treatment5 and vaccines. Therefore, early detection and monitoring of local variant spread has become an important public health task6. Viral RNA of SARS-CoV-2 infected persons can be detected in the sewage collected in wastewater treatment plants (WWTPs) and its concentration has been shown to correlate with case reports7. Moreover, wastewater samples can provide a snapshot of the circulating viral lineages and their diversity in the community through reverse transcription quantitative real-time PCR (RT-qPCR) analysis8,9 or genomic sequencing10–16. Recently, it has been shown that variant prevalence in wastewater correlates with clinical data17,18. Therefore variant monitoring in wastewater may serve as an efficient and complementary approach to genomic epidemiology based on individual patient samples.

However, it is challenging to analyse wastewater samples for their SARS-CoV-2 genomic composition because concentrations of SARS-CoV-2 can be very low, samples may be enriched for PCR inhibitors, viral genomes are typically fragmented and sewage contains large amounts of bacterial, human and other viral DNA and RNA genomes. In addition, the quality of the data obtained from sequencing the mixture of viral genomes is compromised by amplification biases, sequencing errors and incomplete phasing information, which further complicates the detection of an emerging viral lineage that is present in only a small fraction of infected persons.

Here we analysed amplicon-based next-generation sequencing (NGS) data of viral RNA extracted from raw influent samples obtained from multiple Swiss WWTPs (Fig. 1a). To assess reproducibility and quantifiability of sequencing data obtained from wastewater-derived viral RNA, we conducted a series of replicate and spike-in experiments. We then focussed on a close-meshed time-series in two large cities between December 2020 and mid-February 2021, and a ski resort during the holiday season (121 samples in total). These samples cover the period in which the Alpha, Beta and Gamma variants first arrived in Europe. For validation, we then analysed 1,656 mostly daily samples from six WWTPs taken between January and September 2021 to cover the period in which the delta variant emerged. We developed a bioinformatics method named COJAC (Co-Occurrence adJusted Analysis and Calling) for early detection of low-frequency variants emerging in a population and a statistical approach that is suitable for quantitative variant monitoring and estimation of the variant-specific transmission fitness advantage (that is, the relative increase in reproductive number) of any genetic variant of SARS-CoV-2. Our framework works best on close-meshed time-series data.

1Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland. 2SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland. 3Eawag, Swiss Federal Institute of Aquatic Science and Technology, Dübendorf, Switzerland. 4Laboratory of Environmental Chemistry, School of Architecture, Civil and Environmental Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. 5Functional Genomics Center Zurich, ETH Zurich, Zurich, Switzerland. 6Swiss Tropical and Public Health Institute, Basel, Switzerland. 7University of Basel, Basel, Switzerland. These authors contributed equally: Katharina Jahn, David Dreifuss, Ivan Topolsky. E-mail: niko.beerenwinkel@bsse.ethz.ch
Results

Quality of genomic sequencing data derived from wastewater samples. To assess the quality of genomic sequencing data derived from wastewater samples, we compared it to clinical sequencing data. We found that the normalized amplicon coverage obtained from the wastewater samples was not substantially different from the coverage of clinical samples (Fig. 1c) and that it allowed for calling low-frequency mutations in most genomic regions of most wastewater samples we analysed (Supplementary Fig. 1). Replicate and spike-in experiments (Methods) indicate that the relative prevalence of genomic variants can be quantified from the NGS data, although precision is limited at low prevalence. Replication
increases precision, especially in the monitoring of low-frequency variants (Fig. 1b,d and Supplementary Information).

Longitudinal surveillance of the Alpha, Beta and Gamma variants. The variant frequencies in the 122 wastewater samples revealed a continuous increase in the prevalence of the Alpha variant in Zurich starting around mid-December and in Lausanne starting in late December (Fig. 2). Much of the noise in the data can be removed by computing smoothed estimates over time and over signature mutations (Methods). When comparing these estimates of Alpha prevalence to those obtained from clinical samples, we found that they aligned very closely, even though the treatment plants serve only a subset of the respective cantonal populations (Lausanne: 30% of canton Vaud, Zurich: 29% of canton Zurich) (Figs. 3 and 4). For the alpine ski resort, we detected the Alpha variant over the entire period of observation (20–29 December 2020), consistent with the popularity of the ski resort with British tourists as a holiday destination (Fig. 2). Unlike for Alpha, we found almost no evidence for the distinctive signature mutations of Beta or Gamma (Supplementary Information), which is consistent with the observation that neither of the two variants was able to establish itself in the Swiss population.

Early detection of emerging variants with COJAC. For early detection and determination of the timing of the introduction of a variant into a population, we devised the bioinformatics method COJAC that searches for co-occurrence of mutations on read pairs (Methods). Such co-occurrence signals provide high confidence in the presence of the respective strain, as independent biological generation or technical artefacts are both very unlikely to produce such mutational patterns (Supplementary Information). We analysed all amplicons that contained co-occurrences of VOC-specific mutations: four amplicons that each contain two or three Alpha-defining mutations, one amplicon with two signature mutations shared between Beta and Gamma, and one amplicon with two Gamma signature mutations. We found several co-occurrences in our data (Fig. 2 and Supplementary Table 3). The two mutations co-located on amplicon 93 provide the earliest evidence for Alpha in wastewater samples in Zurich on 17 December and in Lausanne on 9 December. In both locations, these dates fall at a time when evidence based on single mutations alone was still very spotty (Fig. 2).

We compared our results to early variant detection based on clinical sequencing data in the respective cantons of Zurich and Vaud. In Switzerland, around 4% of all SARS-CoV-2-positive clinical samples of December 2020 were sequenced. The first clinical evidence of the Alpha variant in canton Zurich was detected in a sample dated 18 December, and in canton Vaud in a sample dated 21 December, the former being 1 d later and the latter being 13 d later than the first wastewater-based evidence. This finding is consistent with those of a retrospective sequencing campaign of March/April 2021 analysing clinical samples collected in November and December 2020. The retrospectively obtained data revealed isolated occurrences of Alpha already on 9 November (3 cases) in canton Zurich, and on 17 December in canton Vaud (1 case) (Supplementary Table 5). For canton Vaud, the retrospective variant detection was still significantly later (8 d) than the first wastewater-based evidence in its capital Lausanne. For canton Zurich, the Alpha-positive samples of 9 November originated from municipalities located outside the catchment area of the studied treatment plant and therefore could not be detected in the analysed wastewater samples.

The co-occurring mutation pair on amplicon 93 that we used for early detection in wastewater is highly specific to Alpha, as it has been observed only 14 times (0.07%) outside of the Alpha lineage in the 21,163 Swiss samples in the GISAID database (Supplementary Table 4) and only 138 times (0.01%) in all 1,397,333 SARS-CoV-2 GISAID samples until 13 February 2021. At later timepoints, we also observe evidence based on the other three Alpha-specific amplicons both in Lausanne and Zurich. In the ski resort, evidence for the presence of Alpha has already been strong based on the analysis of individual mutations over the entire period of observation (20–29 December), and the amplicon-based analysis further supports this observation. For Beta and Gamma, the evidence based on co-occurrence is similarly weak as for the analysis of individual mutations (Supplementary Information). This result aligns with the clinical data for the period of study, with only one Gamma sample detected in canton Zurich (first occurrence on 27 January) and none in canton Vaud. Beta was detected two times in canton Zurich (first occurrence 18 January) and seven times in canton Vaud (first occurrence 14 January).

Estimation of transmission fitness advantage. The transmission fitness advantage of a variant corresponds to the relative increase in reproductive number and provides information on the epidemiological relevance of an emerging variant. We estimated this parameter for Alpha from its prevalence in wastewater separately for Lausanne and Zurich on the basis of a logistic progression model (Methods and Extended Data Fig. 2). Our estimates of the transmission fitness advantage of 46% (confidence interval (CI) of 35–60%) for the Zurich WWTP catchment and 59% (CI 42–84%) for the Lausanne WWTP catchment are in line with those based on regional clinical data and with reports from the United Kingdom (Supplementary Information). Narrowing the clinical data down to the cantonal level, the estimates are still in line with the wastewater data. For Zurich (54%, CI 43–69%, based on 2,062 samples), while for Vaud, the clinical estimates are less precise (75%, CI 34–144%, based on 345 samples) as reflected by the huge confidence interval. To assess how early the transmission fitness advantage can be estimated with acceptable precision, we also computed online estimates of the transmission fitness advantage, that is, using only the data up to the respective time point—46 wastewater samples at most per location (Methods). For canton Vaud, the wastewater-based estimates for the Lausanne WWTP are more precise than the estimates based on hundreds of clinical samples from the canton (Fig. 3b).

For canton Zurich, the estimates are similar to those of thousands of cantonal clinical samples with one outlier around mid-January for Zurich (Fig. 4b and Supplementary Information). Restricting the clinical data to the 115 samples from the city of Zurich, which comprises the majority of the catchment area of the WWTP, shows that the precision of the wastewater-based online estimates is clearly superior (Fig. 4b and Supplementary Information).

Early detection of the Delta variant. To investigate whether our results could be reproduced for the emergence of the Delta variant (B.1.617.2), we analysed additional data from six WWTPs across Switzerland during the introduction and spread of B.1.617 and all its sublineages (denoted B.1.617*) (Fig. 5) for co-occurring signature mutations. Although the RNA concentration in sewage samples at this time was very low due to a lull in the pandemic, we were able to detect signals of B.1.617* and B.1.617.2-specific co-occurrences before or early during the local spread of the variant as observed in clinical samples. In three out of six catchment areas, the wastewater-derived signal was detected before confirmation of the first local B.1.617* positive clinical sample: 118 d earlier in Lausanne, 60 d earlier in Lugano and 4 d earlier in Altenrhein. For the other WWTPs, the variant was first found in the clinical samples of the canton: 10 d earlier in Chur, 22 d earlier in Zurich and 47 d earlier in Laupen. In two of these cases (Lausanne and Lugano), the first detections of the Delta variant were transient and resumed at later dates when the spread of the variant started. In the cases where the detection in wastewater did not precede the detection in clinical samples, the variant was still detected when its prevalence was low. Whether wastewater-based variant detection can precede detection in clinical samples or not depends on the rate at which clinical samples are sequenced. To investigate this effect
Fig. 2 | Longitudinal surveillance of Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) signature mutations in wastewater samples collected at three Swiss WWTPs. Blue color shading encodes the observed fraction of each signature mutation in each sample, pink indicates absence of the mutation and white indicates missing values (due to insufficient coverage). Mutations are grouped by variant and further by amplicon number (yellow boxes) in case multiple mutations co-occur on the same amplicon. Columns labelled ‘Amplicon’ followed by a number (green) show the observed frequency of co-occurrence on the same read pair for all mutations located on the respective amplicon. Mutations occur multiple times on the y axis if they either occur in more than one variant (red) or are located on two overlapping amplicons (orange).
further, we subsampled the clinical sequences at different sample sizes (Supplementary Fig. 4). We found that in general, for low clinical sample sizes, wastewater-based detection precedes clinical detection, while increasing clinical sample size eventually decreases or reverses the advantage of wastewater, with strong diminishing returns.

**Discussion**

We have demonstrated how genomic sequencing of wastewater samples can be used to detect, monitor and evaluate genetic variants of SARS-CoV-2 on a population level. Specifically, we have reported the detection of the local outbreak of the Alpha variant a...
in wastewater in two Swiss cities before it was observed in clinical samples. We expanded our surveillance to six Swiss cities and found that in three of them, the earliest signal of the Delta variant in wastewater pre-dated the first local detection of the variant in clinical samples despite very high clinical sequencing rates at that time in Switzerland (between 66% and 94% of Swiss qPCR-positive samples were randomly selected for sequencing at that time). In the cases where clinical samples provided the first local evidence for the presence of the Delta variant, the first signal in wastewater occurred shortly after and at a time when the local prevalence of the Delta variant was still very low. By subsampling the available clinical samples, we have shown the strong association between the rate

Fig. 4 | Prevalence and fitness advantage estimation for Zurich based on wastewater and clinical sequencing data. a, Top: Alpha (B.1.1.7) prevalence estimates based on wastewater sequencing data and on cantonal clinical sequencing data for Zurich. Bottom: frequencies of Alpha-characteristic substitutions found in wastewater sequencing samples, which are aggregated and smoothed in the top panel. Grey columns show dates without wastewater samples. White columns show dates of failed experiments (insufficient coverage/no SARS-CoV-2 RNA detected in the sample). Orange and red bars indicate the frequency of Alpha-positive cantonal clinical samples, which are also smoothed. The red parts indicate the fraction of Alpha-positive samples that were sequenced retrospectively in March/April 2021 (cut-off date for the GISAID submission date, 21 March 2021). Solid lines represent the smoothed estimates and shaded areas represent 95% confidence bands. b, Estimates of the transmission fitness advantage $f_d$, computed online (Methods) using the wastewater (blue), cantonal clinical (orange) and city clinical (green) sequencing data only until the respective timepoints for Zurich. Solid lines represent the maximum likelihood estimates, shaded areas represent 95% confidence intervals and the horizontal black line indicates offline estimate of $f_d$ based on clinical samples of the Greater Zurich Area dated 14 December 2020 to 11 February 2021 from Chen et al.19.
of clinical sequencing and the delay in variant detection compared with wastewater-based analyses.

While we have shown that early variant detection based on wastewater samples is feasible, we have also observed that the interpretation of single wastewater samples can be challenging. This is because initially, only a small subset of signature mutations is typically observed at low frequencies, which makes it difficult to distinguish between signal and noise in the sequencing data. The high noise level in the data is attributable to the technical challenges that arise in the collection and processing of the raw wastewater sample, the extraction of SARS-CoV-2 RNA and its amplification. Our results suggest that high sampling density across time and replicate sequencing are key elements to improve the signal-to-noise ratio.

We also developed an approach to boost the signal strength in individual samples. This approach is based on the detection of co-occurring signature mutations on the same read pair, as their presence in a sample constitutes a much stronger signal than individual mutations. This approach was particularly valuable for the detection of the Alpha variant which has multiple highly specific mutation pairs and even one triplet that can be detected in this manner. Among the other variants we studied, Beta and Gamma shared one pair of co-occurring signature mutations, with Gamma having one additional variant-specific mutation pair. We detected some early evidence of the introduction of these variants into the Swiss population, but neither of these two variants was able to establish itself in Switzerland against the Alpha variant. For the Delta variant, there are two pairs of signature mutations, which we used for early co-occurrence-based detection: one shared among B.1.617* and one exclusive to B.1.617.2. In general, the usefulness of the co-occurrence analysis for variant identification depends on the exclusivity of co-occurrences and is negatively affected by the presence of recurring mutations in separate lineages\(^{21,22}\). As more and more variants arise and possibly co-exist in a population, shared signature mutations—by chance, convergence or homology—are more likely to occur. In such a case, deconvolution methods\(^{23}\) will become useful to disentangle the aggregate signals of co-occurring variants in wastewater. While we focused in this paper on the introduction of known variants into a new population, the data we generated and the methods we developed can in principle be used and extended to de novo identification of circulating variants and the detection of cryptic variants in unsampled human or non-human animal populations.

Besides early detection, we have shown that sequencing data obtained from wastewater samples can also be used to monitor the local prevalence of a variant, and to estimate its growth rate and...
transmission fitness advantage earlier and on the basis of substantially fewer samples as compared with using clinical samples. Moreover, wastewater samples have the advantage of representation of undiagnosed asymptomatic cases in the data, which are systematically overlooked in clinical sequencing.

Several challenges remain in the analysis and interpretation of wastewater-derived sequencing data. For example, relating the wastewater-derived estimates to a specific local population can be confounded by the movement of people. Switzerland, as many other European countries, has a high level of commuting between geographical locations within the country and from neighbouring regions. The high congruence we observe between clinical and wastewater samples in terms of estimated prevalence and fitness advantage suggests that there is little difference between these two sources of information in regard to the overall presence of infectious individuals regularly present in a city due to residency or daily commute. Another challenge is posed by potential differences in shedding profiles between variants, which may impact quantification from wastewater sequencing, and thus also impact some of the inferred epidemiological characteristics of the variants.

Overall, we have shown that genomic analysis of SARS-CoV-2 variants in wastewater samples can inform epidemiological studies and complement established approaches based on clinical samples. In fact, we have expanded our continued sequencing activities to six wastewater treatment plants across Switzerland for which we publish live updates for the general public as well as for local public health agencies (https://bsse.ethz.ch/cbg/research/computational-virology/sarscov2-variants-wastewater-surveillance.html). Our methodology and continued sequencing campaign provide a blueprint for rapid, unbiased and cost-efficient genomic surveillance of emerging SARS-CoV-2 variants based on longitudinal sequencing of wastewater samples.

Methods

Wastewater sample collection and preparation. Raw wastewater samples were collected from three Swiss WWTPs: Werdholzli, Zurich (64 samples, July 2020–February 2021, population connected: 450,000), Vidy, Lausanne (49 samples, September 2020–February 2021, population connected: 240,000), and an alpine ski resort (8 samples, December 2020) (Fig. 1a and Extended Data Fig. 1). For the validation study, we used mostly daily wastewater samples from Lugano (n = 238, February–September 2021), Lausanne (n = 242, February–September 2021), Zurich (n = 251, January–September 2021), Chur (n = 230, February–September 2021), Lausanne (n = 186, January–July 2021) and Altenrhein (n = 236, February–September 2021). Composite samples (24 h, Zurich and Lausanne) or grab samples (ski resort and Lugano) were collected in 500 ml polypropylene or polyethylene plastic bottles, shipped on ice and stored at 4 °C for up to 8 d before processing. Aliquots of 50 ml were clarified by filtration (2 µm glass fibre filter (Millipore) followed by a 0.2 µm filter (Millipore), Zurich samples) or by centrifugation (4,863 × g for 30 min, Lausanne and ski resort samples). Clarified samples were then concentrated using centrifugal filter units (Centricon Plus-70 Ultrafilter, 10kDa, Millipore) by centrifugation at 3,000 × g for 30 min. Centrifugation was inverted and the concentrate was collected by centrifugation at 1,000 × g for 3 min. The resulting concentrate (up to 280 µl) was extracted using the QiaAmp viral RNA mini kit (Qiagen) according to the manufacturer's instructions, adapted to the larger volumes and eluted in 80 µl. Samples collected after 1 February were further purified using One-Step PCR Inhibitor Removal columns (Zymo Research). RNA extracts were stored at −80 °C for up to 4 months before sequencing.

Genomic sequencing. RNA extracts from wastewater samples were used to produce amplicons and to prepare libraries according to the COVID-19 ARTIC v3 protocol19 with minor modifications. Briefly, extracted RNA was reverse transcribed using the NEB LUNAscript RT SuperMix kit (New England Biolabs) and the resulting complementary DNA was amplified with the ARTIC v3 panel from IDT. ARTIC primers used were: ARTIC V4.1 NCOV-2019 Panel, 500rnx 10011442, IDT ARTIC v3 panel 500rnx 10006768 (IDT). The amplicons were end-repaired and polyadenylated before ligation of adapters using NEB Ultra II (New England Biolabs). Fragments containing adapters on both ends were selectively enriched and barcoded with unique dual indexing with PCR. Libraries were sequenced using the Illumina NovaSeq 6000 and MiSeq platforms, resulting in paired-end reads of 250 bp length each (see Supplementary Information for quality metrics of the sequencing data).

Mutation calling. NGS data were analysed using V-pipe20, a bioinformatics pipeline for end-to-end analysis of viral sequencing reads obtained from mixed samples. Individual low-frequency mutations were called on the basis of local haplotype reconstruction using ShoRAH21. For detecting mutation co-occurrence, we developed a computational tool called COJAC. The ARTIC v3 protocol relies on tiled amplification and some amplicons cover multiple positions mutated in a variant (Supplementary Table 1). As the samples are sequenced with paired-end 250 bp reads, each 400 bp amplicon can be fully observed on the read pairs in close to all instances. Detecting multiple signature mutations on the same amplicon increases the confidence of mutation calls at very low variant read counts. This opens the possibility of earlier detection while variant concentrations are still too low for reliable detection of individual mutations. COJAC takes as input the multiple read alignments (BAM files) and counts read pairs with variant-specific mutational patterns. It can be configured to work with any tiled amplification scheme and to simultaneously search for multiplex variants, each defined by a list of signature mutations. COJAC and its documentation (README file) are available at https://github.com/cbg-ethz/cojac/ or as a bioconda package at https://bioconda.github.io/recipes/cojac/README.html.

Statistical data analysis. For Zurich, we used the 55 sequencing experiments (excluding 1 failed) covering 46 dates ranging from 8 December 2020 to 13 February 2021. When a WWTP sample was sequenced multiple times, we fixed the empirical frequencies of the Alpha signature mutations for a given day by averaging their values between the different sequencing experiments. We only used non-synonymous substitutions for quantification. Frequencies of the Alpha signature substitutions in wastewater-derived NGS data were resampled with replacement and averaged per wastewater sample, before being smoothed across time by local regression using locally weighted scatterplot smoothing (lowess) with 1/3 bandwidth from the Python v3.7.7 library statsmodels v0.12.1.21. This process was repeated 1,000 times to construct bootstrap estimates of the Alpha per-day frequency curves. The smoothed resampled values were used to compute point estimates by averaging the daily Alpha prevalence as well as confidence intervals as the empirical 2.5% and 97.5% quantiles. For the prevalence estimation of Alpha in clinical samples, we used the whole-genome sequencing data from randomly selected SARS-CoV-2 RT-qPCR-positive samples provided by the large diagnostics company Viollier AG22. Daily cantonal relative abundances of variants were estimated as their empirical frequencies in sequenced samples. For each canton, the sequenced cases were resampled with replacement and aggregated into daily relative frequencies of Alpha, which were then smoothed temporally using the same lowess smoother mentioned above. This process was repeated 1,000 times to construct bootstrap estimates of the Alpha daily cantonal relative prevalence, which were aggregated into point estimates and confidence intervals by the same method described above.

Estimation of epidemiological parameters. Following Chen et al.21, we assumed that the relative frequency p(t) of the Alpha variant in the population at time t follows a logistic growth with rate a and inflection point t0. We used the variance of a quasibinomial29 distribution. Although clinical data are not d reported in Chen et al.19 for the Lake Geneva region (population 1.6 million), we used the estimated 2.5% and 97.5% confidence intervals of the model parameters with a generalized linear model. Confidence intervals were computed on the basis of their asymptotically normal distribution. To account for overdispersion due to the inherently noisy nature of wastewater sequencing data, the confidence intervals were computed using the variance of a quasibinomial29 distribution. Although clinical data are not expected to exhibit overdispersion, the same procedure was applied for the sake of consistency. Confidence bands were first generated for the linear predictors, and then back-transformed into confidence bands for the regression curves to ensure that they are restricted to the interval (0,1). Estimates of the logistic growth parameter a were then transformed into estimates of the transmission fitness advantage fa assuming the discrete-time model of Chen et al.21 with generation time γ = 4.8 d such that fa = exp (ag) − 1. Confidence intervals for the logistic growth parameter a were then back-transformed into confidence intervals for the fitness advantage fa. This inference procedure was repeated at multiple timepoints with only the clinical and wastewater sequencing data available at these timepoints, to generate online estimates and confidence intervals of what could have been inferred about fa at that time. These estimates were compared to the estimates of fa reported in Chen et al.21 for the Lake Geneva region (population 1.6 million), which includes Lausanne and the Greater Zurich Area (population 1.5 million). The confidence intervals for these regional estimates of fa were recomputed using
back-transformation of the confidence intervals reported for the regional estimates of $\alpha$, so that they could be meaningfully compared with the ones based on our data.

**Dilution experiment.** RNA samples of cultivated wild-type SARS-CoV-2 (Wuhan strain) and of a clinical Alpha strain were obtained. We measured the RNA concentrations in these samples by quantifying the N1 gene target (on the basis of the CDC N1 gene assay; primers in Supplementary Table 6) using Crystal Digital PCR (Naica system, Still Technologies)\(^+\). A 27 µl pre-reaction volume for Saphire Chip F (C1 4012, Still Technologies) contained sequencing of 5.4 µl of template, 1.35 µl of 2x qScript XL1 One-Step RT-PCR, and N1 primers and probe (2019-nCoRV ROU kit, CN 10006713, Integrated DNA Technologies). Droplet production and PCR were performed on the Naica Geode. Reverse transcription (48°C for 50 min) was followed by denaturation (94°C for 3 min) and 40 cycles (94°C for 30s, 57°C for 1 min) of denaturation and annealing/extension. The Naica Prism3 using the Crystal Reader and Crystal Miner software were used for analysis (Still Technologies).

On the basis of the dPCR measurements, each RNA sample was then diluted in an RNA extract produced from SARS-CoV-2-free wastewater (November 2019, Lausanne) to a final concentration of 200 ng/µl\(^-\). Wild-type and Alpha solutions were then mixed at wild-type to variant ratios of 100:1, 50:1 and 100:1, and each mixture was sequenced 5 times.

**Replicate experiment.** RNA extracts of 25 samples taken in the Lausanne and Zurich WWTP between 8 December 2020 and 4 January 2021 were processed and sequenced a second time. For 23 RNA extracts, sequencing data were successfully produced for both experiments. Another replicate experiment was performed, for which RNA extract was produced as described above from two samples obtained from the Lausanne WWTP on 7 January 2020. The extracts were pooled and subsequently divided into 9 replicate samples for sequencing.

**Patient sequences.** Per-patient SARS-CoV-2 consensus sequences were downloaded from GISAID\(^\text{-}^\text{4}) for all samples collected in Switzerland between 24 February 2020 and 13 February 2021, and not identified as either Alpha, Gamma or Beta (see Supplementary Information for the list of accession numbers).

**Validation experiment for the Delta variant.** We used COJAC as described above to call characteristic mutations co-occurring on amplicons 76 (22917G and 22995A, strain) and of a clinical Alpha strain were obtained. We measured the RNA concentration of 25 samples taken in the Lausanne and Zurich WWTP on 7 January 2020. The extracts were pooled and subsequently divided into 9 replicate samples for sequencing.

**Patient sequences.** Per-patient SARS-CoV-2 consensus sequences were downloaded from GISAID\(^\text{-}^\text{4}) for all samples collected in Switzerland between 24 February 2020 and 13 February 2021, and not identified as either Alpha, Gamma or Beta (see Supplementary Information for the list of accession numbers).

**Validation experiment for the Delta variant.** We used COJAC as described above to call characteristic mutations co-occurring on amplicons 76 (22917G and 22995A, characteristic of B.1.617*) and 91 (27638C and 27752T, characteristic of B.1.617.2) to detect the Delta variant. For each treatment plant, we compared the wastewater sequencing results to clinical consensus sequences of the respective samples. We measured the RNA concentration of 25 samples taken in the Lausanne and Zurich WWTP on 7 January 2020. The extracts were pooled and subsequently divided into 9 replicate samples for sequencing.

**Patient sequences.** Per-patient SARS-CoV-2 consensus sequences were downloaded from GISAID\(^\text{-}^\text{4}) for all samples collected in Switzerland between 24 February 2020 and 13 February 2021, and not identified as either Alpha, Gamma or Beta (see Supplementary Information for the list of accession numbers).

**Validation experiment for the Delta variant.** We used COJAC as described above to call characteristic mutations co-occurring on amplicons 76 (22917G and 22995A, characteristic of B.1.617*) and 91 (27638C and 27752T, characteristic of B.1.617.2) to detect the Delta variant. For each treatment plant, we compared the wastewater sequencing results to clinical consensus sequences of the respective samples. We measured the RNA concentration of 25 samples taken in the Lausanne and Zurich WWTP on 7 January 2020. The extracts were pooled and subsequently divided into 9 replicate samples for sequencing.

**Patient sequences.** Per-patient SARS-CoV-2 consensus sequences were downloaded from GISAID\(^\text{-}^\text{4}) for all samples collected in Switzerland between 24 February 2020 and 13 February 2021, and not identified as either Alpha, Gamma or Beta (see Supplementary Information for the list of accession numbers).

**Validation experiment for the Delta variant.** We used COJAC as described above to call characteristic mutations co-occurring on amplicons 76 (22917G and 22995A, characteristic of B.1.617*) and 91 (27638C and 27752T, characteristic of B.1.617.2) to detect the Delta variant. For each treatment plant, we compared the wastewater sequencing results to clinical consensus sequences of the respective samples. We measured the RNA concentration of 25 samples taken in the Lausanne and Zurich WWTP on 7 January 2020. The extracts were pooled and subsequently divided into 9 replicate samples for sequencing.

**Patient sequences.** Per-patient SARS-CoV-2 consensus sequences were downloaded from GISAID\(^\text{-}^\text{4}) for all samples collected in Switzerland between 24 February 2020 and 13 February 2021, and not identified as either Alpha, Gamma or Beta (see Supplementary Information for the list of accession numbers).

**Validation experiment for the Delta variant.** We used COJAC as described above to call characteristic mutations co-occurring on amplicons 76 (22917G and 22995A, characteristic of B.1.617*) and 91 (27638C and 27752T, characteristic of B.1.617.2) to detect the Delta variant. For each treatment plant, we compared the wastewater sequencing results to clinical consensus sequences of the respective samples. We measured the RNA concentration of 25 samples taken in the Lausanne and Zurich WWTP on 7 January 2020. The extracts were pooled and subsequently divided into 9 replicate samples for sequencing.

**Patient sequences.** Per-patient SARS-CoV-2 consensus sequences were downloaded from GISAID\(^\text{-}^\text{4}) for all samples collected in Switzerland between 24 February 2020 and 13 February 2021, and not identified as either Alpha, Gamma or Beta (see Supplementary Information for the list of accession numbers).
Acknowledgements
RNA samples of cultivated wild-type SARS-CoV-2 (Wuhan strain) and of a clinical
Alpha strain for the dilution experiment were kindly provided by T. Schindler (Swiss
Tropical and Public Health Institute). Supplementary Data File 1 contains the detailed
acknowledgements of the originating and submitting laboratories of the GISAID data.
This work was supported by the SIB Swiss Institute of Bioinformatics as a Competitive
Resource (V-pipe) (N.B.), the Swiss National Science Foundation Special Call on
Coronaviruses (1ICA30 196538, C.O., T.R.J. and T.K.; and 1ICA30 196267, T.S.),
the Swiss Federal Office of Public Health (N.B., C.O. and T.R.J.), the Swiss Federal
Office of the Environment (T.K.), Eawag discretionary funds (C.O. and T.R.J.)
and an EPFL COVID19 grant (T.K.). X.F.-C. was a fellow of the European Union’s
Horizon 2020 research and innovation programme under the Marie Skłodowska-
Curie Grant Agreement (754462).

Author contributions
Conceptualization: N.B., T.K., T.R.J., C.O., T.S., X.F.-C. and I.T. conceptualized the
project. I.T., C.C., K.P.J. and S.N. curated the data. K.J., L.F. and D.D. conducted formal
analysis. N.B., T.K., T.R.J., C.O., T.S. and X.F.-C. acquired funding. X.F.-C., A.K., P.G.,
E.S., C. Bänziger, C.A., F.C., L.C., A.T.C. and M.F. conducted investigations. N.B.,
X.F.-C., K.J., D.D. and I.T. developed the methodology. N.B., T.K., T.R.J., C.O. and T.S.
administered the project. I.T., K.P.J., L.F. and D.D. and K.J. developed the software. N.B.,
T.K., T.R.J., C.O., T.S. and I.T. supervised the project. N.B., I.T., K.J. and K.P.J. validated
the results. K.J., D.D. and K.P.J. performed visualization. N.B., K.J., D.D. and I.T. wrote
the original draft. N.B., T.K., T.R.J., C.O., T.S., K.J., K.P.J., L.F., X.F.-C., D.D., C.A., S.N.,
C.C., C. Bänziger and C. Beisel reviewed and edited the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Extended data is available for this paper at https://doi.org/10.1038/s41564-022-01185-x.
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41564-022-01185-x.
Correspondence and requests for materials should be addressed to Niko Beerenwinkel.
Peer review information Nature Microbiology thanks Chris Lauber and the other,
anonymous, reviewer(s) for their contribution to the peer review of this work.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made. The images or other third
party material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the article’s
Creative Commons license and your intended use is not permitted by statutory regulation
or exceeds the permitted use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2022
Extended Data Fig. 1 | Geographical locations of wastewater treatment plants (WWTPs) surveyed for this study. Geographical locations of wastewater treatment plants (WWTPs) surveyed for this study. WWTP catchment areas are highlighted in light red. Cantons in which the WWTPs are located are highlighted in grey. Population numbers are for the WWTP catchment areas and surrounding cantons, respectively. Location of the ski resort is illustrative. Source: Federal Office of Topography. Wastewater treatment plant catchments of Switzerland: Eawag (2014) updated from https://www.dora.lib4ri.ch/eawag/islandora/object/eawag%3A5599.
Extended Data Fig. 2 | Logistic growth model fitted to variant proportions derived from wastewater and clinical samples. Dots with error bars represent daily empirical proportions of Alpha-positive clinical samples (orange), or average empirical proportions of Alpha-characteristic substitutions in wastewater (blue). Error bars are 95% Wilson confidence intervals. Solid lines represent maximum likelihood fitted values of the logistic model used to infer transmission advantage. Shaded areas represent 95% confidence bands.
Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- n/a Confirmed
- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
- Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
- Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

| Data collection | No software used. |
|-----------------|------------------|

Data analysis

Automation of data analysis: https://github.com/cbg-ethz/pangolin (commit 0f92e9390f3788cfd1b9e6ed76227cb8866b6ac); V-pipe v: https://github.com/cbg-ethz/pangolin (commit 0f92e9390f3788cfd1b9e6ed76227cb8866b6ac); R: v3.6.1; Python v3.7.7; statmodels v0.12.1; custom code: https://github.com/cbg-ethz/cojac/tree/master/notebooks

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

raw reads available under: PRJEB44932; for privacy reasons, the human-mapping reads have been removed before upload; name of ski-resort from which wastewater samples were taken is kept private

pre-processed data used for the analysis is available here: https://github.com/cbg-ethz/cojac/tree/master/notebooks/data

Clinical genomic data was obtained from Cov-Spectrum: https://cov-spectrum.org/ and is found in the data folder
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☐ Life sciences  ☐ Behavioural & social sciences  ☑ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/ns-reporting-summary-flat.pdf

Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Study description | Raw wastewater samples from different wastewater treatment plants were analyzed for variants of SARS-CoV-2. |
|-------------------|--------------------------------------------------------------------------------------------------|
| Research sample   | The samples represent 24h composite liquid fraction samples from WWTPs collecting the excreta from the entire connected population in the respective catchments, with residential population sizes ranging from <10000 (a ski resort) to 450000 (city of Zurich). The choice of the sampling locations was made to maximise connected population, as well as covering the different linguistic regions of the country. The ski resort was chosen as a popular touristic destination. |
| Sampling strategy | 24-hour composite samples (and one grab sample) were collected by wastewater treatment plant operators and shipped one ice to our laboratories for analysis. We decided on daily samples to match the reporting frequency used in Switzerland for pandemic reporting (daily cases, daily hospitalisations etc.), and ramped up to that frequency as quickly as feasible. No power calculation were made in the dilution and replication experiments; simply, we settled on a sample size that would approximately emulate real world number of samples in a given week, where the proportion of variants should be almost stable. |
| Data collection   | Wastewater treatment plant operators collect raw wastewater samples routinely to demonstrate performance of their wastewater treatment process. They diverted subsamples to us on ice in plastic or polypropylene bottles. After preparation, the samples were analysed and the data collected using Illumina NovaSeq and MiSeq platforms. |
| Timing and spatial scale | For the city of Lausanne, 6 samples were collected in the period of Sep to Nov 2020 (baseline) and then daily from 8.12.2020 to 31.12.2020 (with samples missing from 28 and 30 Dec). From Jan 2021 to mid Feb 2021, samples were collected every two to five days. From mid February onwards, samples were collected approximately each day. In Zurich, 18 samples were collected in the period Jul to Nov 2020 (baseline) and then daily from 8 Dec to 31 Dec (with only the sample of 30 Dec missing). From Jan 2021 to mid Feb 2021, samples were collected every two to five days. From mid February onwards, samples were collected approximately each day. In the Swiss Alpine ski resort, samples were collected daily from 21 Dec 2020 to 29 Dec 2020 (grab sample on 21 Dec, composite samples for all other days). In the cities of Laufen, Lugano, Altenrhein and Chur samples were collected approximately each day starting early February. The choice to sample daily was made to match the general reporting strategy of Switzerland (daily cases, daily hospitalisation). |
| Data exclusions   | No data was excluded. Please note that three samples were not shipped by wastewater treatment plant personnel due to logistics on particular days (28 and 30 Dec in Lausanne and 30 Dec in Zurich). |
| Reproducibility  | No experiments were involved. Each sample is unique for the day it represents and cannot be taken multiple times. 25 samples were resequenced a second time, one pooled sample was sequenced 10 times. Sequencing yielded data for 23 out of the 25 samples. For the second experiment, 9 out of 10 were successfully sequenced and analyzed. The reproducibility has been assessed in Fig 1B and Supplementary Fig. S3. |
| Randomization    | There was no manipulation on the populations analyzed, therefore we did not randomize. |
| Blinding         | There was no randomization, therefore no blinding. |

Did the study involve field work?  ☐ Yes  ☑ No

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems | n/a | Involved in the study |
|---------------------------------|-----|-----------------------|
| Antibodies                     | ☑   | Antibodies            |
| Eukaryotic cell lines           | ☑   | Eukaryotic cell lines |
| Palaeontology and archaeology   | ☑   | Palaeontology and archaeology |
| Animals and other organisms     | ☑   | Animals and other organisms |
| Human research participants     | ☑   | Human research participants |
| Clinical data                   | ☑   | Clinical data |
| Dual use research of concern    | ☑   | Dual use research of concern |

| Methods                          | n/a | Involved in the study |
|---------------------------------|-----|-----------------------|
| ChiP-seq                        | ☑   | ChiP-seq |
| Flow cytometry                  | ☑   | Flow cytometry |
| MRI-based neuroimaging          | ☑   | MRI-based neuroimaging |

Antibodies

Antibodies used

Describe all antibodies used in the study; as applicable, provide supplier name, catalog number, clone name, and lot number.
Validation

Describe the validation of each primary antibody for the species and application, noting any validation statements on the manufacturer’s website, relevant citations, antibody profiles in online databases, or data provided in the manuscript.

Eukaryotic cell lines

Policy information about cell lines

Cell line source(s) State the source of each cell line used.

Authentication Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.

Mycoplasma contamination Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.

Commonly misidentified lines (See ICLAC register) Name any commonly misidentified cell lines used in the study and provide a rationale for their use.

Palaeontology and Archaeology

Specimen provenance Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information). Permits should encompass collection and, where applicable, export.

Specimen deposition Indicate where the specimens have been deposited to permit free access by other researchers.

Dating methods If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.

☐ Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Ethics oversight Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals For laboratory animals, report species, strain, sex and age OR state that the study did not involve laboratory animals.

Wild animals Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.

Field-collected samples For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.

Ethics oversight Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants

Policy information about studies involving human research participants

Population characteristics Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write “See above.”

Recruitment Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

Ethics oversight Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.
Clinical data

Policy information about clinical studies
All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration
Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.

Study protocol
Note where the full trial protocol can be accessed OR if not available, explain why.

Data collection
Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.

Outcomes
Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

Dual use research of concern

Policy information about dual use research of concern

Hazards
Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No | Yes
---|---
☐ | Public health
☐ | National security
☐ | Crops and/or livestock
☐ | Ecosystems
☐ | Any other significant area

Experiments of concern

Does the work involve any of these experiments of concern:

No | Yes
---|---
☐ | Demonstrate how to render a vaccine ineffective
☐ | Confer resistance to therapeutically useful antibiotics or antiviral agents
☐ | Enhance the virulence of a pathogen or render a non-pathogen virulent
☐ | Increase transmissibility of a pathogen
☐ | Alter the host range of a pathogen
☐ | Enable evasion of diagnostic/detection modalities
☐ | Enable the weaponization of a biological agent or toxin
☐ | Any other potentially harmful combination of experiments and agents

ChIP-seq

Data deposition
☐ Confirm that both raw and final processed data have been deposited in a public database such as GEO.
☐ Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links
May remain private before publication.
For “Initial submission” or “Revised version” documents, provide reviewer access links. For your “Final submission” document, provide a link to the deposited data.

Files in database submission
Provide a list of all files available in the database submission.

Genome browser session
(e.g. UCSC)
Provide a link to an anonymized genome browser session for “Initial submission” and “Revised version” documents only, to enable peer review. Write “no longer applicable” for “Final submission” documents.

Methodology

Replicates
Describe the experimental replicates, specifying number, type and replicate agreement.

Sequencing depth
Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and
Flow Cytometry

Plots
- Confirm that:
  - The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
  - The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
  - All plots are contour plots with outliers or pseudocolor plots.
  - A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation
- Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.

Instrument
- Identify the instrument used for data collection, specifying make and model number.

Software
- Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a community repository, provide accession details.

Cell population abundance
- Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.

Gating strategy
- Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.

Magnetic resonance imaging

Experimental design

Design type
- Indicate task or resting state; event-related or block design.

Design specifications
- Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.

Behavioral performance measures
- State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).

Acquisition

Image type(s)
- Specify: functional, structural, diffusion, perfusion.

Field strength
- Specify in Tesla

Sequence & imaging parameters
- Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.

Area of acquisition
- State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.

Diffusion MRI
- Used
- Not used
## Preprocessing

**Preprocessing software**

Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).

**Normalization**

If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.

**Normalization template**

Describe the template used for normalization/formation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.

**Noise and artifact removal**

Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).

**Volume censoring**

Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.

## Statistical modeling & inference

**Model type and settings**

Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).

**Effect(s) tested**

Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.

**Specify type of analysis:**

- [ ] Whole brain  
- [ ] ROI-based  
- [ ] Both

**Statistic type for inference**

Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.

**Correction**

Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).

## Models & analysis

**n/a**

- [ ] Functional and/or effective connectivity
- [ ] Graph analysis
- [ ] Multivariate modeling or predictive analysis

**Functional and/or effective connectivity**

Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).

**Graph analysis**

Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).

**Multivariate modeling and predictive analysis**

Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.